CommercialPrior AuthMedium impact
08.01.35i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes medical necessity criteria for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialty pharmaceutical used in acute lymphoblastic leukemia (ALL) treatment. The billing team must now verify that claims meet the new medical necessity requirements before submission to avoid denials.
Action Required
By January 1, 2025: Billing team must implement medical necessity verification for HCPCS code J9019 (Asparaginase Erwinia Chrysanthemi). Before processing claims, verify that documentation supports medical necessity criteria outlined in policy 08.01.35i. Update billing software or claims submission checklist to flag J9019 claims for pre-submission medical necessity review. Coordinate with oncology providers and clinical staff to ensure required documentation is present on all Rylaze® claims. Claims submitted without documented medical necessity will be denied.